These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 37435061)
41. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. Fionda C; Soriani A; Malgarini G; Iannitto ML; Santoni A; Cippitelli M J Immunol; 2009 Oct; 183(7):4385-94. PubMed ID: 19748980 [TBL] [Abstract][Full Text] [Related]
42. Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity. Oliviero B; Mantovani S; Varchetta S; Mele D; Grossi G; Ludovisi S; Nuti E; Rossello A; Mondelli MU J Hepatol; 2017 Jun; 66(6):1130-1137. PubMed ID: 28192188 [TBL] [Abstract][Full Text] [Related]
43. Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Reiners KS; Topolar D; Henke A; Simhadri VR; Kessler J; Sauer M; Bessler M; Hansen HP; Tawadros S; Herling M; Krönke M; Hallek M; Pogge von Strandmann E Blood; 2013 May; 121(18):3658-65. PubMed ID: 23509156 [TBL] [Abstract][Full Text] [Related]
44. DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy. Cifaldi L; Melaiu O; Giovannoni R; Benvenuto M; Focaccetti C; Nardozi D; Barillari G; Bei R Front Immunol; 2023; 14():1197053. PubMed ID: 37359555 [TBL] [Abstract][Full Text] [Related]
45. All About (NK Cell-Mediated) Death in Two Acts and an Unexpected Encore: Initiation, Execution and Activation of Adaptive Immunity. Ramírez-Labrada A; Pesini C; Santiago L; Hidalgo S; Calvo-Pérez A; Oñate C; Andrés-Tovar A; Garzón-Tituaña M; Uranga-Murillo I; Arias MA; Galvez EM; Pardo J Front Immunol; 2022; 13():896228. PubMed ID: 35651603 [TBL] [Abstract][Full Text] [Related]
46. Che-1 is targeted by c-Myc to sustain proliferation in pre-B-cell acute lymphoblastic leukemia. Folgiero V; Sorino C; Pallocca M; De Nicola F; Goeman F; Bertaina V; Strocchio L; Romania P; Pitisci A; Iezzi S; Catena V; Bruno T; Strimpakos G; Passananti C; Mattei E; Blandino G; Locatelli F; Fanciulli M EMBO Rep; 2018 Mar; 19(3):. PubMed ID: 29367285 [TBL] [Abstract][Full Text] [Related]
47. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay. Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272 [TBL] [Abstract][Full Text] [Related]
48. NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. Le Maux Chansac B; Moretta A; Vergnon I; Opolon P; Lécluse Y; Grunenwald D; Kubin M; Soria JC; Chouaib S; Mami-Chouaib F J Immunol; 2005 Nov; 175(9):5790-8. PubMed ID: 16237071 [TBL] [Abstract][Full Text] [Related]
49. Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells. Meng F; Zhang S; Xie J; Zhou Y; Wu Q; Lu B; Zhou S; Zhao X; Li Y J Hematol Oncol; 2023 Jun; 16(1):62. PubMed ID: 37316891 [TBL] [Abstract][Full Text] [Related]
50. ADCC against MICA/B Is Mediated against Differentiated Oral and Pancreatic and Not Stem-Like/Poorly Differentiated Tumors by the NK Cells; Loss in Cancer Patients due to Down-Modulation of CD16 Receptor. Kaur K; Safaie T; Ko MW; Wang Y; Jewett A Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33440654 [TBL] [Abstract][Full Text] [Related]
51. Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity. Bernard PL; Delconte R; Pastor S; Laletin V; Costa Da Silva C; Goubard A; Josselin E; Castellano R; Krug A; Vernerey J; Devillier R; Olive D; Verhoeyen E; Vivier E; Huntington ND; Nunes J; Guittard G J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35589278 [TBL] [Abstract][Full Text] [Related]
52. A new baby in the c-Myc-directed transcriptional machinery: Che-1/AATF. Folgiero V; Sorino C; Locatelli F; Fanciulli M Cell Cycle; 2018; 17(11):1286-1290. PubMed ID: 29943642 [TBL] [Abstract][Full Text] [Related]
53. Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma. Zhang Z; Su T; He L; Wang H; Ji G; Liu X; Zhang Y; Dong G Tohoku J Exp Med; 2012 Jan; 226(1):59-68. PubMed ID: 22189020 [TBL] [Abstract][Full Text] [Related]
54. TSG101 interacts with apoptosis-antagonizing transcription factor and enhances androgen receptor-mediated transcription by promoting its monoubiquitination. Burgdorf S; Leister P; Scheidtmann KH J Biol Chem; 2004 Apr; 279(17):17524-34. PubMed ID: 14761944 [TBL] [Abstract][Full Text] [Related]
55. β-catenin attenuation leads to up-regulation of activating NKG2D ligands and tumor regression in Zou M; Al-Yahya S; Al-Alwan M; BinEssa HA; Khabar KSA; Almohanna F; Assiri AM; Altaweel A; Qattan A; Meyer BF; Alzahrani AS; Shi Y Front Immunol; 2023; 14():1171816. PubMed ID: 37483610 [TBL] [Abstract][Full Text] [Related]
56. Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms. Fernandes de Oliveira Costa A; Olops Marani L; Mantello Bianco T; Queiroz Arantes A; Aparecida Lopes I; Antonio Pereira-Martins D; Carvalho Palma L; Santos Scheucher P; Lilian Dos Santos Schiavinato J; Sarri Binelli L; Araújo Silva C; Kobayashi SS; Agostinho Machado-Neto J; Magalhães Rego E; Samuel Welner R; Lobo de Figueiredo-Pontes L Front Immunol; 2022; 13():768592. PubMed ID: 36211444 [TBL] [Abstract][Full Text] [Related]
57. HIPK2 sustains apoptotic response by phosphorylating Che-1/AATF and promoting its degradation. De Nicola F; Catena V; Rinaldo C; Bruno T; Iezzi S; Sorino C; Desantis A; Camerini S; Crescenzi M; Floridi A; Passananti C; Soddu S; Fanciulli M Cell Death Dis; 2014 Sep; 5(9):e1414. PubMed ID: 25210797 [TBL] [Abstract][Full Text] [Related]
58. Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers. Oshima T; Sato S; Kato J; Ito Y; Watanabe T; Tsuji I; Hori A; Kurokawa T; Kokubo T Mol Cancer; 2013 Jun; 12():60. PubMed ID: 23758976 [TBL] [Abstract][Full Text] [Related]
59. Porcine UL16-binding protein 1 expressed on the surface of endothelial cells triggers human NK cytotoxicity through NKG2D. Lilienfeld BG; Garcia-Borges C; Crew MD; Seebach JD J Immunol; 2006 Aug; 177(4):2146-52. PubMed ID: 16887974 [TBL] [Abstract][Full Text] [Related]
60. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Stanietsky N; Simic H; Arapovic J; Toporik A; Levy O; Novik A; Levine Z; Beiman M; Dassa L; Achdout H; Stern-Ginossar N; Tsukerman P; Jonjic S; Mandelboim O Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17858-63. PubMed ID: 19815499 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]